Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Linda, Schönborn"'
Autor:
Rhea Edmonds, Linda Schönborn, Sunke Habben, Maria Paparoupa, Andreas Greinacher, Frank Schuppert
Publikováno v:
Clinical Case Reports, Vol 11, Iss 1, Pp n/a-n/a (2023)
Abstract Vaccine‐induced immune thrombotic thrombocytopenia (VITT) is a rare clinical condition that has emerged during the mass immunization against SARS‐CoV‐2. Reports indicate that VITT may also be induced by other vaccines, such as the huma
Externí odkaz:
https://doaj.org/article/6d6b1d781d88458a85859b03bd8c0ad2
Autor:
Thomas Thiele, Karin Weisser, Linda Schönborn, Markus B. Funk, Gabriele Weber, Andreas Greinacher, Brigitte Keller-Stanislawski
Publikováno v:
The Lancet Regional Health. Europe, Vol 12, Iss , Pp 100270- (2022)
Summary: Background: Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a severe adverse event of SARS-CoV-2 vaccination. We describe the characteristics of patients reported in Germany based on the Brighton Collaboration (BC) case definiti
Externí odkaz:
https://doaj.org/article/a13747a6f0e946678ba01d84f7395742
Publikováno v:
Aktuelle Rheumatologie. 47:490-501
ZusammenfassungIn diesem Übersichtsartikel beschreiben wir die klinischen und paraklinischen Charakteristika der Vakzin-induzierten immunthrombotischen Thrombozytopenie (VITT) und fassen den gegenwärtigen Kenntnisstand zur Pathogenese zusammen. Bei
Autor:
Albrecht Günther, Dirk Brämer, Mathias W. Pletz, Thomas Kamradt, Sabine Baumgart, Thomas E. Mayer, Michael Baier, Angelina Autsch, Christian Mawrin, Linda Schönborn, Andreas Greinacher, Thomas Thiele
Publikováno v:
Vaccines, Vol 9, Iss 11, p 1344 (2021)
Background and Objectives: Vaccine induced thrombotic thrombocytopenia (VITT) may occur after COVID-19 vaccination with recombinant adenoviral vector-based vaccines. VITT can present as cerebral sinus and venous thrombosis (CSVT), often complicated b
Externí odkaz:
https://doaj.org/article/61ada4457095468f9fce453292077d0e
Autor:
Andreas Greinacher, Kerstin Weitmann, Linda Schönborn, Ulf Alpen, Doris Gloger, Wolfgang Stangenberg, Kerstin Stüpmann, Nico Greger, Volker Kiefel, Wolfgang Hoffmann
Publikováno v:
Blood Advances, Vol 1, Iss 14, Pp 867-874 (2017)
Abstract: Transfusion safety includes the risk of transmission of pathogens, appropriate transfusion thresholds, and sufficient blood supply. All industrialized countries experience major ongoing demographic changes resulting from low birth rates and
Externí odkaz:
https://doaj.org/article/ce072df9d5a24031938d24cc43d101ee
Autor:
Andreas Greinacher, Linda Schönborn, Florian Siegerist, Leif Steil, Raghavendra Palankar, Stefan Handtke, Alexander Reder, Thomas Thiele, Konstanze Aurich, Karen Methling, Michael Lalk, Uwe Völker, Nicole Endlich
Publikováno v:
Seminars in Hematology. 59:97-107
Vaccine-induced immune thrombotic thrombocytopenia (VITT; synonym, thrombosis with thrombocytopenia syndrome, is associated with high-titer immunoglobulin G antibodies directed against platelet factor 4 (PF4). These antibodies activate platelets via
Autor:
Linda Schönborn, Thomas Thiele, Lars Kaderali, Albrecht Günther, Till Hoffmann, Sabrina Edigna Seck, Kathleen Selleng, Andreas Greinacher
Publikováno v:
Blood. 139:1903-1907
Vaccine-induced thrombotic thrombocytopenia (VITT) is triggered by vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2-S). In this observational study, we followed VITT patients for changes in their reactivity of
Autor:
Andreas Büttner, Michael Lalk, Raghavendra Palankar, Stefan Kochanek, Reiner K. Mailer, Evi X. Stavrou, Uwe Völker, Karen Methling, Thomas Renné, Konstanze Aurich, Leif Steil, Thomas Thiele, Lea Krutzke, Martin Beer, Maike Frye, Kathleen Selleng, Theodore E. Warkentin, Chandini Rangaswamy, Hanna Englert, Martina Wolff, Stephan Michalik, Linda Schönborn, Nicole Endlich, Florian Siegerist, Alexander Reder, Boris Fehse, Christian Hentschker, Jan Wesche, Stefan Handtke, Andreas Greinacher, Kati Franzke
Publikováno v:
Blood
SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using biophysical techniques, mouse models, and analysis of VITT patient samples, we identified de
Publikováno v:
New England Journal of Medicine. 385:2202-2205
Autor:
Linda Schönborn, Thomas Thiele, Max Esefeld, Khalil El Debuch, Jan Wesche, Sabrina E. Seck, Lars Kaderali, Martina Wolff, Theodore E. Warkentin, Andreas Greinacher
Publikováno v:
Journal of thrombosis and haemostasis : JTHREFERENCES. 20(11)
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a prothrombotic, heparin-induced thrombocytopenia (HIT)-mimicking, adverse reaction caused by platelet-activating anti-platelet factor 4 (PF4) antibodies that occurs rarely after adenovirus